Seagen, Inc. (NASDAQ: SGEN), relating to its proposed sale to Pfizer Inc. Under the terms of the agreement SGEN shareholders are expected to receive $229.00 in cash per share they own.
Seagen, Inc. (NASDAQ: SGEN), relating to its proposed sale to Pfizer Inc. Under the terms of the agreement SGEN shareholders are expected to receive $229.00 in cash per share they own.